Alzheimer's News Today Home | Alzheimer's News Today
WEBFosgonimeton fails to meet goal in Alzheimer’s clinical trial: Data. Fosgonimeton, an investigational medication from Athira Pharma, failed to significantly improve cognitive and daily functioning in adults with mild to …
FDA approves donanemab, now Kisunla, to treat early …
WEBJul 3, 2024 · The U.S. Food and Drug Administration (FDA) has approved Eli Lilly ‘s antibody therapy donanemab, now Kisunla, for certain adults with Alzheimer’s disease. Specifically, Kisunla is indicated for patients with …
ALZ-801 for 2 years seen to sustain cognition in early …
WEBSep 22, 2023 · These are the top-line findings of an ongoing Phase 2 clinical trial (NCT04693520), whose two-year data also showed that …
- Occupation: Science Writer
- Estimated Reading Time: 5 mins
September is World Alzheimer’s Month; Sept. 21 is Alzheimer’s Day
WEBSep 6, 2022 · Since 2009, ADI has released a World Alzheimer Report on World Alzheimer’s Day and will again on Sept. 21. The reports, which make recommendations …
Alzheimer's therapy foralumab nasal spray cleared by FDA for...
WEBJul 11, 2024 · Foralumab, an investigational nasal spray being developed by Tiziana Life Sciences, has been cleared by the U.S. Food and Drug Administration (FDA) for …
FDA Approves Aduhelm, First Targeted Alzheimer’s …
WEBJun 7, 2021 · The therapy’s development has been both unusual and tumultuous. Data from an early Phase 1b clinical trial called PRIME (NCT01677572) suggested that the treatment could safely slow …
News Archives - Alzheimer's News Today
WEBZunveyl, therapy that may be easier on GI system, wins FDA approval. The U.S. Food and Drug Administration (FDA) has approved the oral therapy Zunveyl (benzgalantamine), …
Topline results of Phase 3 studies of simufilam for …
WEBFeb 8, 2024 · Two Phase 3 clinical trials are testing the effectiveness of simufilam, an experimental oral therapy that’s designed to improve cognition in people with Alzheimer’s disease.. Top-line results from the …
Simufilam aids cognition in 47% of Alzheimer's …
WEBMar 14, 2023 · The Phase 2 trial runs for two years, with treatment safety and tolerability being measured over that time. Enrolled patients are randomized to a full two years of simufilam at 100 mg twice daily, or to …
Full Phase 3 Trial Data Support Lecanemab for Early …
WEBDec 6, 2022 · About 1.5 years of treatment with lecanemab (BAN2401) — now under regulatory review in the U.S. — was found to significantly slow the progression of dementia symptoms in people with early-onset …